Latest Healthcare News

Page 17 of 197
Booster Innovation Fund has invested $200,000 in TheiaNova, a University of Auckland spinout developing a self-administered eye drop for keratoconus. The seed-stage bet accounts for 0.76% of BIF’s portfolio, keeping the exposure modest while adding an early biotechnology asset.
Ada Torres
Ada Torres
22 Sept 2026
Rua Bioscience delivered a sharp rise in customer revenue and secured a UK agreement expected to generate NZ$10 million over two years. But PwC disclaimed an audit opinion, warning the company may not have enough cash without another capital raise.
Ada Torres
Ada Torres
22 Sept 2026
Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.
Ada Torres
Ada Torres
22 Sept 2026
Microba shareholders would own about 67% of an enlarged Genetic Signatures under a proposed all-scrip merger valued at approximately A$51 million. The deal combines roughly A$29.6 million of FY2026 revenue and identifies up to A$3 million in potential annual cost synergies, but remains subject to a long list of approvals.
Victor Sage
Victor Sage
22 Sept 2026
Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.
Ada Torres
Ada Torres
22 Sept 2026
ReNerve has converted regulatory approvals into its first commercial NervAlign Nerve Cuff surgeries in Hong Kong and Malaysia, expanding activity to seven jurisdictions. The milestones arrive as FY26 sales climbed 88% to $510,357 and the company builds out its US distribution network.
Victor Sage
Victor Sage
21 Sept 2026
Orthocell has recorded the first commercial sales of its Remplir nerve repair product in Thailand, opening a new market estimated at US$84 million. The launch gives the company another distributor-led growth channel, although near-term sales are expected to remain modest.
Ada Torres
Ada Torres
21 Sept 2026
Telix will acquire ITM in a proposed US$1.65 billion deal that combines a commercial radioisotope supplier with Telix’s precision medicine and therapeutic pipeline. The transaction could give Telix greater supply-chain control and entry into a validated cancer treatment market, but it also brings dilution, integration risk and an unresolved FDA pathway for ITM-11.
Ada Torres
Ada Torres
21 Sept 2026
Freedom Care Group’s 29%-owned Koala Disability Care has agreed to sell its Tuggerah disability care and registered NDIS provider business for $2.238 million plus GST. The deal could provide a cash distribution to Freedom Care, although the amount and timing of its proceeds remain unclear.
Ada Torres
Ada Torres
18 Sept 2026
Memphasys has signed a three-year exclusive distribution agreement covering the Czech Republic, Slovakia and Kazakhstan, with minimum purchases worth approximately A$674,000. The deal expands Felix’s European footprint while adding dedicated commercial leadership in the region.
Victor Sage
Victor Sage
18 Sept 2026
Austco Healthcare delivered record FY26 revenue and statutory profit, with stronger margins, cash generation and a modest recovery in contracted orders entering the new financial year. The company is pairing that momentum with further reseller consolidation, including the $2.88 million acquisition of Medical Communications Systems.
Victor Sage
Victor Sage
17 Sept 2026
Epiminder has enrolled the 75th patient in its DETECT study, meeting its September target as the US site network expands to 21 centres. The company expects to reach 100 enrolments in November and remains focused on completing the 210-patient study by the end of the first half of calendar 2027.
Ada Torres
Ada Torres
17 Sept 2026

Browse the archive

Full archive